Dr Mark Ashton (Chair)
Dr Mark Ashton joined UniQuest in 2010 and is currently the Executive Director of Intellectual Property Commercialisation. Before joining UniQuest Dr Ashton was the Executive Vice President, Business Development at the international biotech, Evotec AG, a company that focuses on drug discovery alliances and development partnerships with the pharmaceutical and biotech industry. Prior to leading the business development group at Evotec, Dr Ashton was President, Discovery Services at Evotec, responsible for the company’s Drug Discovery division, a division that carried out projects involving high throughput screening, parallel synthesis and medicinal chemistry to pre-clinical development. Dr Ashton has worked within the biotech and pharmaceutical industry since the early 1990’s and has both operational and commercial experience of a wide range of life science projects. He has worked with most of the major pharmaceutical companies and a number of biotech companies around the world negotiating agreements totalling in excess of $100M. Dr Ashton is the author and co-author of a number of peer reviewed scientific publications and patents including new chemical entities that have progressed to human clinical trials.
Dr Dean Moss
A UQ alumnus, Dean Moss has 30 years’ experience in science, academia, business, management and commercialisation in Australia, USA and the UK. He has been managing director or senior business development executive of several health and biotech companies worldwide, including Agen Biomedical, Launch Diagnostics, AMRAD ICT, AMRAD Biotech, and United Drug. He established his own start-up business in the UK, York Medical Technologies. Prior to moving into the commercial world, Dean was principal R&D scientist at Agen Biomedical. He also worked as an NHMRC research scientist at the Princess Alexandra Hospital, the Royal Brisbane Hospital and the Queensland Institute of Medical Research. He is a recipient of the Campion-Ma-Playoust Memorial Award for Medical Research. Dean is a board member of several Australian companies and was a member of the investment committee of the pre-seed venture funds Uniseed, the Medical Research Commercialisation Fund and the New Zealand Government’s KiwiNet. He is a current member of the NHMRC Health Innovation Advisory Committee. He has contributed to raising over $100m in venture capital investment.
Professor Brandon Wainwright
Professor Wainwright is the Director of The University of Queensland’s Institute for Molecular Biology (IMB) where he leads a laboratory focused on understanding the genetic pathways behind skin cancer and medulloblastoma, a type of brain tumour that occurs predominantly in children. He is Chair of the European Molecular Biology Laboratory (EMBL) Australia and serves on the boards of Life Sciences Queensland and the Australian Genome Research Facility as well as several national and international scientific review committees. In 2015, Professor Wainwright chaired the Queensland Institutes of Health. Professor Wainwright completed his undergraduate and postgraduate studies at the University of Adelaide. He secured a postdoctoral fellowship at St Mary’s Hospital at Imperial College London where he worked on the first human genome project and made significant discoveries in human molecular genetics as a Medical Research Council Senior Research Fellow. He returned to Australia in 1990 to join UQ’s Centre for Molecular and Cellular Biology (now IMB).
Professor Alastair McEwan
Professor McEwan is Pro-Vice Chancellor (Research) and Dean of The University of Queensland Graduate School. He currently has oversight of research grant applications, engagement and performance as well as development of researchers including the higher degree research students. He is a Professor of Microbiology in the School of Chemistry & Molecular Biosciences and a member of the Australian Centre for Infectious Disease Research at The University of Queensland. He holds a PhD in Biochemistry from the University of Birmingham and held research fellowships at the University of Illinois at Urbana-Champaign and the University of Oxford prior to joining The University of Queensland in 1993. His research interests are in bacterial physiology and pathogenesis and the role of transition metal ions in host-pathogen interactions, supported by NHMRC Program and Project grants over the last decade.
Dr Andrew Harvey
Dr Harvey heads the Queensland Emory Drug Discovery Initiative as a Senior Director at UniQuest. Prior to joining UniQuest, Dr Harvey was the Vice President of Drug Discovery at Bionomics Limited (Adelaide, Australia), a publicly-listed discovery and development company working across oncology, neuroscience and inflammation. In this role, he was responsible for leading chemistry and IP in programs ranging from hit identification to phase II clinical development, including two programs partnered with Merck & Co. While at Bionomics, Dr Harvey worked closely with the Cancer Therapeutics Cooperative Research Centre (CTx) as an industry partner and a member of the CTx operations group. Previously, Dr Harvey was an NHMRC Industry Fellow at the Walter and Eliza Hall Institute (Melbourne, Australia), where his research focused on autoimmune disease. He obtained his PhD in biological chemistry at the University of Canterbury (Christchurch, New Zealand).